{"id":641138,"date":"2024-10-10T10:35:20","date_gmt":"2024-10-10T07:35:20","guid":{"rendered":"https:\/\/en.buradabiliyorum.com\/milaboratories-gets-10m-for-a-platform-play-to-accelerate-genomic-research\/"},"modified":"2024-10-10T10:35:20","modified_gmt":"2024-10-10T07:35:20","slug":"milaboratories-gets-10m-for-a-platform-play-to-accelerate-genomic-research","status":"publish","type":"post","link":"https:\/\/buradabiliyorum.com\/en\/milaboratories-gets-10m-for-a-platform-play-to-accelerate-genomic-research\/","title":{"rendered":"#MiLaboratories gets $10M for a platform play to accelerate genomic research"},"content":{"rendered":"
\n

Advances in DNA sequencing and the vast amounts of genomic data being produced by next-generation sequencing (NGS) technology<\/a> have created a startup opportunity to build software for biologists so they can more easily analyze this big data and take the next leap. It could help when it comes to developing new vaccines, cancer treatments and so on.<\/p>\n

For the last four years, MiLaboratories<\/a>, a San Francisco-based startup with an R&D facility in Bilbao, Spain, has been building a computational biology platform to make it easier for biologists to process, analyze and aggregate their data. It incorporates features like data visualization and generative AI to boost usability.<\/p>\n

Its platform is also designed to be a marketplace for other scientists so that they can distribute more specialized computation tools in the form of app<\/a>s to keep expanding the utility for the genomics research community. MiLaboratories target scientists whose skillsets span biology, computer science<\/a> and math \u2014 so-called bioinformaticians.<\/p>\n

\u201cIt\u2019s a \u2018no code\u2019 style approach for biologists and<\/em> we also release an [open source] SDK \u2014 software development kit \u2014 allowing bioinformaticians to build real applications,\u201d CEO Stan Poslavsky tells TechCrunch.<\/p>\n

\u201cDuring my and our founders\u2019 scientific career, we saw a huge inefficiency . . . in how modern therapies, how modern drugs, are developed,\u201d he explains. \u201cBecause of this friction between the data \u2014 the big data, generated by the biologists, the sequencing data \u2014 and the data analysis which is not available for them.\u201d<\/p>\n

While there are \u201cthousands\u201d of software programs and tools that can do analysis of NGS data, he says most have been developed within academia, where the focus tends to be on utility rather than usability.<\/p>\n

There\u2019s also a need for biologists to aggregate and integrate results from multiple analyses, he says. \u201cIn a unified picture, allowing you to understand what\u2019s going on. And that\u2019s the place where our platform helps dramatically,\u201d he suggests.<\/p>\n

The startup hopes its platform will free up bioinformaticians from being called upon to deal with the grunt work of genomic data processing so these multidisciplinary scientists can apply their skillset to the more complex tasks of building algorithms that might help advance cutting-edge science.<\/p>\n

\u201cBioinformaticians are actually spending a lot of time just doing a monkey job of running the software for biologists,\u201d says Poslavsky. \u201cTo process this data, you need to have Linux machines, go over SSH, run complicated software tools to get the analysis done and get the insight from the data.\u201d<\/p>\n

\u201c[A doctor] has no skills to do this on Linux, on HPC [high performance computing] cluster, because he has other things to do. And that\u2019s what most bioinformaticians in the companies and academia are doing, actually, just this monthly job of running the tools.\u201d<\/p>\n

\"\"
MiLaboratories founding team, with Stan Poslavsky second from left<\/span>Image Credits:<\/strong>MiLaboratories<\/span><\/figcaption><\/figure>\n

On Thursday, MiLaboratories officially took the wraps off its SDK, Platforma.bio<\/a>, which lets third-party developers contribute apps \u2014 although it\u2019s been in alpha and beta testing for several years. (Poslavsky says \u201caround 300 labs\u201d have been using the beta, and \u201caround 20\u201d apps have been made available through the platform, so far.)<\/p>\n

\u201cThe first applications that are available in the platform are built around our biological and bioinformatic applications, which are very popular . . . [with] companies and people involved in immune therapy developments. But we already have . . . a good selection of collaborations and people willing to bring their applications on the platform, both from academia and from the industry,\u201d he adds.<\/p>\n

The 2021-founded startup is also announcing a $10 million Series<\/a> A funding round to continue development, with a focus on investing in community building.<\/p>\n

\u201cThe key reason for raising money is just to plug more hands into the development of our platform. We are hiring more engineers. We are hiring what is called developer advocates, who are propagating the technology around \u2014 primarily \u2014 the academic community, because most bioinformatics software is developed in academia.\u201d<\/p>\n

\u201cFor the upcoming year [we will] focus on the propagation of the technology around the community, and engaging community to build their apps, to wrap their existing software, to deliver them through the platform,\u201d he adds.<\/p>\n

MiLaboratories\u2019 Series A is led by Madrid-based Kfund, with participation from Acrobator Ventures, EGB Capital, Courtyard Ventures, Somersault Ventures, Speedinvest and Ten13.<\/p>\n

Commenting in a statement, Miguel Arias, general<\/a> partner of Kfund, said: \u201cInvesting in platforms that bridge the gap between developers (in this case bioinformaticians) and business users (in this case biologists) is at the core of what we want to do in our fund. There is tremendous potential in democratizing access to complex data enabling the delivery of immunological insights.\u201d<\/p>\n

MiLaboratories offers its software for free to academics but it\u2019s also taking revenue via a paid model for commercial users. Per Poslavsky the startup is approaching 100 paying customers at this stage. <\/p>\n

\u201cMany of the big pharma companies \u2014 like Moderna, Bristol-Myers Squibb \u2014 they are our customers,\u201d he notes, adding: \u201cWe have revenue \u2014 good revenue \u2014 allowing us to not be so dependent on venture money.\u201d <\/p>\n

At the start of 2022, the startup raised a $2.5 million seed round. It also previously took in a small pre-seed from a few angels.<\/p>\n

Discussing the challenges of developing the computational biology platform, Poslavsky says the staggering amount of data being generated by NGS meant startup had to pay very careful attention to ensuring processing efficiency to avoid generating \u201ccrazy costs\u201d.<\/p>\n

\u201cThe amount of data generated in the space are actually, well, crazy,\u201d he emphasizes. \u201cBig pharma companies, our customers . . . they have petabytes of genetic data generated so far. So that\u2019s huge scale.\u201d<\/p>\n

MiLaboratories has developed what Poslavsky couches as a \u201cvery sophisticated\u201d and \u201cmathematically proven\u201d technology which allows for many sorts of calculations to be performed in \u201ca very optimized way.\u201d He suggests this tech \u2014 which it has patented \u2014 enables the platform to reach 10x efficiency compared to some other types of computational workflow.<\/p>\n

\u201cThat\u2019s a very important thing. It\u2019s hidden from the eyes of the biologist \u2014 because the valuable proposition for the biologist is \u2018I want to click buttons and get insight\u2019 \u2014 but it\u2019s very important for the business owners.\u201d<\/p>\n

Competition wise, Poslavsky names Seqera<\/a> (and its Nextflow software) as the closest rival \u2014 in terms of popularity and value proposition. There are also open source tools for NGS processing, such as Galaxy<\/a>, but MiLaboratories reckons its platform offers researchers a more accessible route to data insights. <\/p>\n<\/div>\n

If you liked the article, do not forget to share it with your friends. Follow us on\u00a0Google News<\/a><\/span>\u00a0too, click on the star and choose us from your favorites.<\/span><\/strong><\/p><\/blockquote>\n

\n

If you want to read more like this article, you can visit our Technology<\/a><\/span> category.<\/strong><\/p>\n<\/blockquote>\n

Source<\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Advances in DNA sequencing and the vast amounts of genomic data being produced by next-generation sequencing (NGS) technology have created a startup opportunity to build software for biologists so they can more easily analyze this big data and take the next leap. It could help when it comes to developing new vaccines, cancer treatments and…<\/p>\n","protected":false},"author":1,"featured_media":641139,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/techcrunch.com\/wp-content\/uploads\/2024\/10\/unnamed_44e5de.png?resize=1200,816","fifu_image_alt":"","footnotes":""},"categories":[18],"tags":[151516,74839,152267,152268,70917],"class_list":["post-641138","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology","tag-biotech-health","tag-fundraising","tag-genomic-research-computational-platform","tag-milaboratories","tag-startups"],"_links":{"self":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/641138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/comments?post=641138"}],"version-history":[{"count":0,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/641138\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media\/641139"}],"wp:attachment":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media?parent=641138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/categories?post=641138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/tags?post=641138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}